Formulation, Development and Evaluation of Fast Disintegrating Piroxicam Tablets| Stephy Publishers

 

SOJ Pharmaceutical Sciences - (SOJPS)| Stephy Publishers

Abstract
Piroxicam is a non-steroidal anti-inflammatory drug used in the treatment of osteo arthritis, rheumatoid arthritis, ankylosing spondylitis, classified in the Bio pharmaceutics Drug Classification system as a Class II drug because it has low solubility and high permeability. It demonstrates a slow and gradual absorption via the oral route and has a long half-life of elimination, rendering a prolonged therapeutic action and a delayed onset of anti-inflammatory and analgesic effect. Thus, an attempt is made to formulate piroxicam fast disintegrating tablet so that it helps to render faster onset of anti-inflammatory and analgesic effect. To increase the solubility of piroxicam solid dispersion method is opted in the present investigation. Study proposes the use of PVPk30 to prepare solid dispersion of piroxicam and comparison of its in-vitro dissolution with pure piroxicam. Fast Dissolving tablets can be prepared by conventional direct compression method using solid dispersion. For better Hardness, less friability, faster wetting time and less moisture uptake combination of both MCC and Mannitol are used in the formulation.

Introduction

Fast disintegration drug delivery system

In this period, fast disintegrating drug delivery system (FDDDS) began to gain popularity and acceptance since they can disintegrate/ dissolve quickly in the oral cavity upon contact with saliva, resulting in solutions or suspensions form of the administered medicine.Fast disintegrating drug delivery systems (FDDSs) are the systems which disintegrate even in the absence of additional water and release the active ingredient quickly. The development of pharmaceutical technology in past years has presented the development of alternative dosage forms for patients who may have difficulty in swallowing of conventional tablets. Among the drug delivery systems, the fast-disintegrating tablets (FDTs) are the more acceptable form because of its convenience of self-administration, compactness. Pediatric and geriatric patients, who have difficulty in swallowing, uncooperative patients, where the traditional tablets and capsules administration is inconvenient, the fast dissolving/ disintegrating tablets are perfect alternative. According to European Pharmacopoeia, the FDT disintegrate in less than three minutes. The basic approach used in development of FDT is the use of super disintegrants which provide instantaneous disintegration and thereby releasing the drug in saliva. Taste of the drug is one of the most important parameters which should be considered for the development of FDTs. Oral administration of bitter drugs with an acceptable degree of palatability can be achieved by taste masking approach. The Zydis (Catalent Pharma Solutions, Somerset, NJ) based on lyophylization technology is the first approved FDDDS.

Drug Profile

Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class and is used to relieve the symptoms of painful inflammatory conditions like arthritis. Piroxicam works by preventing the production of endogenous prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling.

To read more #PharmaceuticalSciences
https://www.stephypublishers.com/sojps/fulltext/SOJPS.MS.ID.000501.php

 

More #Openaccessjournals
https://www.stephypublishers.com/